The N(l/iollal lllstitlltefo r OcclIpatiollal Safe ty and Health (N IOSH) recei ved a reques t from th e United Sta tes Fish and W ildlife Service (FWS) to -det erm ine if there is a relationship bet ween acou sti c neu renn a and fish hatch ery work. The req uest was triggered by a repo rtfrom all FWS eniployee W / 1O susp ect ed the possibility of such all association. In vest igators m ed data p ro vided by the pers onnel office ofthe FWS to calcu late the incidenee ofacou sti c neuronia am ong fi sh ha tch ery wo rkers, and th en to COII!pare it with national rates.
tic neuromas.'-' Other than neurofibro matosis 2, only noise has been proposed as a risk factor for acoustic neuroma; this possibilit y is suggested by the findings of one population-based study.?
The usual presentin g symptom of acoustic neuroma is a unilateral sensorineural hearing loss. Other common symptoms are tinnitu s, vertigo, and unsteadiness. The diagnosis can be made by brainstem auditc ry evoked potentials and by gadoli nium-enhanced magnetic resonance imaging (MRI). Surgical removal is the primary form of treatment.
Th is case series highlights the difficulti es of determining the etiology of occupational neoplasms, including acoustic neuroma. The purpose of repor ting this cluster is to make clinicians aware of the possib le link between 'acoustic neuroma and workplace exposures, as weil as to heighten sensitivity to the relationship between occupational exposures and other neoplasms. It is the responsibility of the eliri ieian to include an occupational history in the general medical history and to take it into account when perfonning the physical examination.
Background
The National Inst itute for Occ upatio nal Safety and Health (NIOSH) received a request from the United States Fish and Wildl ife Serv ice (FWS) to determine il' there is a relationship between acoustic neuroma and fish hatchery work. The request was triggered by areport from an FWS emp loyee who suspected the possibility of such an association.
As part of the Departrnent of the Interior, the FWS endeavors to conserve, protect, and enhance fish and wildlife and their habitats for the continuing benefit of the American people. The FWS's major responsibilities are to care for migratory birds, endangered specie s, certain marine mammais, and freshwater and spawning fish. The FWS operates 51 I wildlife refuges, 72 hatcheries, nine fish health centers, and five fish technology cen ters acros s the U.S.
Methods
Investigators used data provided by the person nel office of the FWS to caleulate the incidenee of acoustic neuroma among fish hatchery worker s, and then co mpared it with national rates. The FWS is a small organ ization, and, accor ding to the emp loyee who triggered the investigation, most of the staff biologists know each other. Thi s employee prov ided a list of those current and form el' employees who, to his perso nal knowledge, had developed brain tumors . The list was com piled during 1996 and 1997. NIOSH inves tigators contacted these persons, 01' their survivors , by telephone to determine iftheir medical history was consis tent with a diag nosis of acoustic neuroma. Four curre nt 01' forme r fish hatchery workers did have such a history, and their medical records were obtained to confirm the diagnosis. All cases of acoustic neuroma had been diagnosed by MRI 01' computed tomogra phy (CT).
Investigators also visite d three fish hatcheries and a fish health center in the Pacific Nor thwes t to better understand past and curre nt exposure to chemical, physical, and biological hazards.
Results
Based on the number of full-time equivale nt employees repo rted by the FWS personnel office, investigators determined that the FWS ernployees accou nted for 154,290 person -years worked during the 22-year period from 1976 through 1997 ; the annual average was 7,013 personyears. (Co mputerized records of this information were not available prior to 1976.) The work force at the FWS is relatively stab le; turnover has been low , and there have been no significa nt expansions 01' dow nsizing . Therefore, the estimated total person-time worked since 1961, the date that the first case bega n emp loyment (01' "exposure") , was 259,485 person -years . Fish hatchery workers accounted for approximately 10% of the emp loyees at FWS, 01' 25,949 person-years, The list provi ded by the employee who initiated the inves tigation contai ned the names of 14 current or former FWS employees who had deve loped brain tumors , One curre nt emp loyee and three retirees-all of whom had worked in fish hatcheries-had a history consis tent with acoustic neuroma, and these diag noses were confirmed by a review of their medical records (see case histories below). Seven others on the list did not have a history cons istent with acoustic neuroma-that is, they had either a malignant tumor, aneurysm, meningioma, or metastatic disease to the brain. The remain ing three persons cou ld not be reac hed.
Case 1. Case I began work as a fish biologist for the FWS in 1966. Except for one 3-year assignme nt to a regio nal office, he had worked in cold -water hatcheries until he retired in 1994. In 1981, he sought medical treatment for tinnitus, dizziness, and a progressive right-
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Your local Microline sales representative will make all the arrangements with your office and hospital. His hearing loss progressed to the point that he co uld no lon ger hear on the teleph one, and he so ught treatment in Feb ruary of 1989. His audiog ra m revealed asevere senso rine ura l hear ing loss; his speech reception thre shold was 40 dB , and his speec h discrimination in the left ear was 30 %. CT re vea led a lesion in the left ce rebe llopontine angle and a wide ning of the internai auditory ca na l that was con sistent with aco ustic neu roma. Th e tum or was surgically re moved. He had no person al or famil y history of neurofibromatosis 2.
Case 4. Case 4 began work as a fis h biologist for the FWS in 1963 . After spe nding hi s entire ca reer in co ldwa ter fish hatcheries, he retired in 1995. In 1991 , he so ug ht treatm ent for a 5-to 6-year history of pro gressive rig ht-side d hea rin g loss. Aud iologic testin g reve aled a severe se nso ri ne ura l hearing loss; hi s speec h reception threshoId was 30 dB , and his speech discrim ination in the right ea r was 44 %. MRI revealed an aco ustic neurom a, whic h was surgi ca lly rem oved. He had no person al or fami ly history of neurofib romatosis 2. Based on these fo ur co nfirme d cases, the incid ene e of acou stic neurom a amo ng for mer fis h hatch ery workers is estimated at 15041 per 100,000 per son-years, a rate that is more than 15 tim es higher than the rate amo ng the ge ner al population .r " If there are ot her unr ep orted ca ses , thi s rate wo uld, of co urse, be high er.
Discussion
Health events ofte n occ ur in a elu ster, which scientis ts define as an unu su al con cent rati on of cases in a spec ific area or tim e. Multipl e cases amo ng workers of a different 3 6 age or ge nder gro up than is usual might co nstitute an occ upationa l elu ster. Sometimes these elu ste r events have a co mmo n cau se, but oft en their occ urr ence is merely co inc ide ntal. Rare diseases suc h as aco ustic neurom a can occas ionally clus ter in a way tha t is statistically unlikel y but stiil not re lated to ex pos ure ." In instances wh ere the nu mber of cases is sma ll, it ca n be d ifficult to ascertai n a co mmon ca use, es pecially when there are no appa rent tum or-cau sin g exp osures.
Th is paper repo rts an appa rent elu ster of aco ustic neuromas among fish hatchery workers in wh ich the incidene e was much h igh er th an tha t see n in the gene ral population. Th e magni tud e of the ex cess, however , mus t be int erpreted ca utio us ly becau se of the poten tial for detection bias. The prevalen ce of undiagnosed aco ustic neurom a at autopsy is 0.8 to 0.9% .9. 10 As not ed ea rlie r, the annual incidenee of symptornatic, diagno sed aco us tic neuroma is approxi mately 1 per 100 ,000 . It is co nce iva ble that FW S employees might have been alerted to a possibl e conneetion bet ween aco us tic neu roma and workplace exp osure and ment ion ed thi s to thei r ph ysician s. If so, they wo uld have been more lik el y to have their aco us tic neuroma diagnosed . Thi s possibil ity is unii kel y, howe ver , becau se the index case was diagn osed so me tim e aft er one of the othe r cases had been detected . More over, the em ployee who initi ated the investi gati on did not co mpile his list of . employees with br ain tumors until1 996 and 1997 , se vera l yea rs after the last of the fo ur cases had been diagno sed. Inter view s with the fou r cases indicated that they we re not awa re of an y othe r suc h cases in the FWS or that there was any person al co mmunica tion between the cases at the time of diagno sis. In additio n, medical record review s and interviews ind ica te that all cases we re already syrn ptomatic at the tim e of dia gn osis.
An important issue to consider whe n evaluating the possibility of an occupational cause of a tumor is the laten cy per iod . Laten cy peri od s vary by tumor type, but typically are 15 to 20 years. Th e shortes t suc h laten cy period amo ng occupa tio na l expos ures appears to be that of acute myelog en ou s leu kemi a following ex pos ure to be nze ne, whic h averages 10 years." At the othe r end of the range, it ca n tak e mesoth eli om a as lon g as 30 years to develop after ex po sure to asbestos."
In thi s study, the int erval between the star t of ernpl oyment at a fish hatch er y and a diagn osis of aco ustic neuro ma ranged fro m 8 to 28 years (mea n: 20). It sho uld be kept in mi nd that the employee who had the shortes t latency period had lived on hatcheries as a child and ofte n ass isted his fat he r wi th his dut ies as a career fis h biologist. Th erefore, his ex pos ure exceeded his length of ern ployme nt by man y yea rs . are oxytetracycline, ch lora mphenicol, and several sulfa drugs . Anes thetics inelude tricai ne methanesulfonate (MS -222) and quinaldine. Disinfectants inelude formalin, malachite green, benzalkoni um ch loride , chlori ne, iodine, and po tassium permanganate. Herbicides and pesticides inelude 2,4 -d ich loro phe noxyacetic acid, 2,4 ,5-trichlorophenoxyacetic acid, sod ium arsenite, warfarin, and carbaryl. Many other substances have been or are being used in FWS, state, and private hatc heries.
Forty years ago, on ly a very few of these substances had bee n approved and registered by the Food and Drug Admi nistration. Althoug h protocols for the trea tme nt of various fish diseases did exist, it was poss ible to deviate from these protocols on an as-nee ded basis. This practice came under the scrutiny of the FDA in the mid-1960s . As aresult, the FDA's Bureau of Veterinary Med icine notified the Bureau of Spor t Fis heries and Wild life that all chemicals use d at federal, state, and private hatcheries mus t be cleared and registered for spec ific uses aga inst design ated species under defined co nditions. T he FWS then polled all federal hatcheries, as weil as 14 state un its, to deter mine which chemicals required top priority for elearance. T he initial list incl uded 95 substa nces: 23 herbicides, 18 internaI treatments for fish disease, 16 external treatments and disinfectants, 13 pes t con troIs for species other than fish, eight fis h co ntro Is, seven fish transport aids , seve n anes the tics , and three dyes ." T hese substances we re entered into the approval process, and the list was updated perio dica lly. But by 1982, only IS of these co mpounds had received FDA or Environme ntal Protection Agency approval for aquatic or fishery use.':'
Ma lachite green. Interviews wit h the four FWS employees with acoustic neuroma, as we il as wit h several long-term employees at three salmon hatcheries in the Pacific Nort hwest, revea led a concern that adverse heal th effects might have bee n caused by ma lac hite green. Ma lachite green was ban ned from use in hatcheries in the mid -1980s, except as an investigational new drug for use in endangered species. Prior to then , there had been extensive use of ma lach ite green, and wo rkers had worn no personal protect ive equipment when handli ng it.
Malachite green is a triphen ylmethane dye used in aquaculture for the treatment of funga l and parasitic infections in fish and their eggs . It is structura lly simi lar to gen tia n violet, a carci nogenic trip hen yl methane dye .'? It is reduced to so me extent in the bo dy to leucomalach ite green, which has a longer half-Iife. Ma lac hite gree n is mut agen ic in Salmone lla typhitnurium T A98 in the pres -
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There does not appear to be an inerease in adverse events in subjeets who reeei ved oraleonlraeeplives and loratadine.
CLARI TIN-D 24 HDUR Exlended Release Tablets (pseudoephedrine compo nent) are eontraind ieated in patientstakingmonaamineoxidase inhibi lors and for 2 weeks after stopping use of an MAO inhibitor. The antihypertens ive elf eets of bela-adrenergi e bloeking agents. Ad verse events did not appear 10 signifieantly di fler based on age, sex, or race, although the numberof non-whit es was relati vel y small.
In addition to those adverse events reported above, the following adverse events have beenreported in fewer than 2% of patient s who reeeived CLARITlN-D24HOUR Exlended Release Tabl ets:
AutonomicNervous System: A1t ered laerimalion, flushing, inereased sweating, rnydri asis, Ihirs!.
Body As A WhoJe: Abnormal vision, asthenia, baek pain, chest pain, eonjunet ivitis, earacne. eye pain, laeial ederna, fever, flu-like syrnptorns, leg crarnps, Iymphadenopathy, malaise, rigors, linnitus.
CardiavascuJar System: Hyperten sion,palpitalion, taehyeardi a. Skin andAppendages: Acne, pruritus. UrinarySystem: Oligur ia, mielurition frequeney, urinary retenlion, urinarytraetinfeetion.
. . . Addilional adverse events reportedWith the combinatlnn 01 loratadine and pseudoephedrine ineludeabnormal hepati c funetion, aggressive reaet ion, anxiety, apat hy, eonfusion, euphoria, paroniria, postural hypotension, syneope, urtiearia,vertigo,weight gain.
'. The following additional adve rse events have been reported With CLARITIN Tabl ets: abdominal dlstress, alopeeta. allered mi eturition, altered salivalion, amnesia, anaphylaxis, angioneurolie edema, blepharospasm, breast enlargemenl, breast pain, bronchitis, deereased libido, dermatilis, dry hair, dry ski n, eryt hema mulliforme, hypoeslhesia, impaired concentration, irnpotence, inereased appetite, laryngili s, menorrhagia, nasal dryness, peripheral edema, photosensilivity reaeti on, purpura, rash, seizures, sneezing, suprave ntrieular laehyarrhythmias, upper respiratory infeetion, urinarydl scol oration.
Pseud oephedrine may eause mild CNSsti mulation in hypersensitive pati ent s. Nervou sness, exeitability, resllessness, di zziness, weakness, or insomnia ma y occur, Headaehe, drowsiness, laehyeardia, palpit ation, pressor aetivity, and eardiae arrhythmias have been reported. Sympathomimelie drugs have also been assoc iated wil h ol her unt oward etteets. such as lear, anxiety , teaseness. Iremor, hallueinanons, seizures, pallor, respiratory difli eulty, dysuria, and cardiovasculareollapse.
There havebeen postmarketing reports of mechaniealuppergastrointestinaltrael obstrueli onand esophageal perlor ation in patients takinga previously marketed formulati on of CLARITIN-D 24 HOUR Extended Rel easeTablet s. Insome, bul not all, of these cases, pati ents have had known upper gastrointestinal narrowi ng or abnormal esophageal peristalsis, It is not known whether this reformulalion of CLARITIN-D 24 HOUR Exlended ReleaseTablels hasthe potential for this adverse event (see PRECAUTIONS, DOSAGE AND ADMINISTRATION). OVERDOSAGE: In the evenl of ove rdosage, general symplomatie and supporli ve measureS should be instilut ed prompll y and maintained for aslong as neeessary. Trealment of overdosage would reasonably eonsist of emesi s (ipeeae syrup), exeept in palients with impaired eonseiousness, followed by the administralion of aetivated ehareoal to absorbany rem aining drug. It vamiting is unsueeessful , or eontraindieated, gastrie lavage should be perlormed with normal saline, Sal ine ealharties may also be of value for rapid dilulion of boweleontents. Loratadine is not eliminat ed by hemodi al ysis. It is not knownif loratadineis eliminated by peril onealdial ysis.
Somnolenee, laehyeardi a, and headaehe have been rep orted wilh doses of 40to 180mgof loratadine. Inlargedoses, sympalhomimeties may give rise10 giddiness, headaehe, nausea, vamiling, sweating, thirsl, laehyeardia, preeordial pain, pal pitations, diffieulty in mi eturition, museul ar weakness and tensene ss, anxiely, resllessness, and insomnia, Many patienl s ean presenta toxie psyehosis with delusions and hallu einati ons. Some may develop eardiae arrhythmias, elreulatory eollapse, eonvulsions, coma, and respir atoryfailure.
The oral median lethal dose for the mi xlure of the two drugs was greater than 525 and 1839 mg/kg in miee and rats, respeelivel y (approximately 10 and 58 times Ihe maximum reeammended human dail y oral dose on a mg/m' basis), The oral medi an lelhal dose for loratadine was grealer Ihan5000 mg/kg in rat s and miee (greate r than 2000 times the maximum reeommended human daily oral dose on a mg/m' basis). Si ngle oral doses of loraladine showed no elfeets in rats, mi ee, and monkeys at doses as highas 10limes themaximum reeommend ed human daily oral doseon a mg/m' basis. methyldopa, meeamylamine, reserpine, andverat rumalkaloids may be redueed by sympath omimelies. Inereased eetopiepaeemaker aetivity ean oeeur when pseud oephedrine is used eoneomilanllywi th digitalis. Drug/Laboralory Tesl Interaelions: The in vi/raaddition of pseudoephedrine to sera contai ning the eardiae isoenzyme MBof serum ereatinine phosph okinase progressivel y inhibits the aelivity of the enzyme. Theinhi bilion beeomes completeover 6 hours. caretncaenes ts, Mulagenesis, Impairmenl 01 Fertilily: There are noanimal or laboralory studieson Iheeombina lion produet loratadine and pseudoephedrine sulfate10evaluatecarcinoqenesls, rnutaq enesis, orimpairment01fertility.
Inan18-month eareinogenieity studyin mi ee and a 2-year study in rats loratadlne was adminislered in the diet at doses upto 40 mg/kg (miee) and 25 mg/kg (rats). In theeareinogenieity studies pharmaeokinetieassessments wereearried outto determineanimal exposureto thedrug. AUC data demonstraled Ihat the exposure of miee given40 mg/kg of loratadine was 3.6 (Ioratadine)and 18 (aetive metabolite) times higherIhanin humans gi venthe maximum reeommended dai ly oral dose. Exposure 01 rats given 25 mg/kg of loraladine was 28 (Ioratadine) and 67 (active mel abolite) times higher Ihan in humans given themaximum reeommendeddai ly oral dose. Malemieegi ven40 mg/kg had a signifieanlly higher incidenee of hepatoeellular lumors (eombined adenomas and eareinomas) Ihan eoneurrent controis. In rats, a signifieanlly higher incidenee of hepaloeellular lumors (eombined seenomas and eareinomas) was obse rved in males gi ven10mg/kgand in males and femal es given 25 mglkg. Theelinieal signilieanee 01 these lindings during long-term use of loraladine is noi known.
Two-year feeding studies in miee and rats conducted under the auspices 01 the Nati onal Toxieology Programs (NTP) uneavered no evi denee 01eareinog enie potential of ephedrinesulfate at doses up to 10 and 27 mg/kg, respeeti vel y (approximalel y 16% and 100% of the maximum reeomm end ed human dail y oral dose of pseucoephedrine sulfateona mg/m' basis), . In mutageniei ty studieswilh loratadinealane, Ihere was no eVIdenee of mut ageni e polential in reverse (Ames) Dr forward point rnutati on(CHO-HGPRT) assays, or in the assay for DNA damage (Rat Primary Hepatoeyte Unseheduled DNA Assay) or in two assays for ehromosomal aberralions (Human Peripheral Blood Lymph oeyle Cla stogenesis Assay and the Mouse Bone Marrow Erylhroeyte Mieronueleus Assay). In the Mouse Lymphoma Assay, a postnve finding oeeurr ed in the nonaelivaled but not the aetivated phase of Ihestudy.
Deereased fert ility in male rats, shown by lowerfemal e conception rates, oeeurred at 64mg/kg of loratadine (approxi mately 50 times the maximum reeomm ended humandail y oral dose based on mg/m') and was reversibl e with eessation of dosing oLorat adine had no effeet on mal eor femal efertilityor reproduction inIhe raI at24 mglkg (approximalel y 20limesthe maximum reeommended humandail y oral dose on a mg/m' basis). Pregnaney Calegory B: The eombinalion produet loraladine and pseudoephedr ine sulfate was evaluated for leratogenlelty In rals and rabbits. There was noevidenee of leratogeniei ty in rep roductionstudies wilhIhis eombination of thesameelinieal ralio(1:24) aiarai doses upto 150mglkg (approximately 5 limes Ihe maximum reeomm ended human dail y oral dose on a mg/m' basis) in ral s, and 120mg/kg (8 times the maximum reeommendedhumandail y oral doseona mg/m' basis) in rabbits. Similarly, no evidenee of animal teratogenieity in rals and rabbits was reported at oral doses upto 96 mg/kg of lorat adine alane (approximately 75 and 150 times, respeelivel y, Ihe maximum humandail y oral dose on a mg/m' basis).Thereare, however, no adequate and well-eontrolled studies in pregnanlwomen. Beeau se animal reproducti on studies are noi always predieti ve of human response, CLARITIN-D 24 HOUR Extended Rele ase Tabl ets should be used during pregnaney onl y if elearly needed. Nursing Molhers: It is noi known if this eombination produet is exereted in humanmilk. However , loraladine when administered alane and its metabolile desearboelhoxyloratadine pass easily into breast milkand achieve eoneentrations Ihat are equival entto plasma level s, wilh an A U C _/A U C , ,~ratio of 1.17 and 0.85 fortheparentand aelive mel abolite, respeeti vel y. Following asingle oral doseof 40mg, asmall amount of loratadineand met abolite was exereted intoIhebreast mi lk (appr oximatel y 0.03% of 40 mg over 48 hour s), Pseud oeph edrine adminislered alane also distribul es inlo breast mil k of Ihe laetating human femal e. Pseudoephedrine eon eentrations in milkare eonsistently higherthan Ihose inplasma. Thetotalamount of drug in milkas judged by Ihe area underthe eurve (AUC) is 2 to 3 limes greater than in pl asma. The fraetion of a pseudoephedr ine doseexereted in milkis eslimated 10 be 0.4% to 0.7%. A deei sionshould be made whether to diseont inue nur sing or to di seont inuethedrug, taking inlo aeeount Ihe importanee of Ihe drug to Ihe molher. Caution should be exereise d when CLARITIN-D 24 HOUR Extended Rel ease Tabl ets areadministeredto anursi ngwoman. Pedialrie Use: Safety and efleetiveness in ehildren belowtheage of 12years havenot beenestablished. ADVERSE REACTIONS: Inf ormationon adverse reaet ions is provided from pl aeebo-eonlrolled studies involving over 2000patienl s, 605 of whom reeeived CLARITIN-D 24 HOUR Extended Release Tabl el s onee daily for up to 2 weeks. In Ihese sludies, Ihe incidenee of adverse evenls reported wilh CLARITIN-D 24 HOUR Extended Release Tablel s was similar to those reported with Iwiee-dail y (qI2 h) 120 mg sustained-release pseudoephedri nealane.
REPORTED ADVERSE EVENTSWITH ANINCIDENCE OF 6  4  5  4  Insomnia  5  1  9  1  Pharyngitis  5  5  5  5  Dizziness  4  2  3  2  Coughing  3  2  3  1  Fatigue  3  4  1  2  Nausea  3  2  4  2  Nervousness  3  1  4  1  Anorex ia  2  <1  2  0  Dysmenorrhea  2  2  2 1 Adverse events oeeurring ingreater Ihan or equalto 2%of CLARI TlN-D 24HOUR Extended Release Tablets-treated patients. butthat were mare common inthe plaeebo-treated group, inelude headaehe. Thi s produel should not be usedby patient s whoarehypersensilive to it or to anyof its ingredienls. Due to its pseudoephedrineeomponent, this produel should noi be used by pafient s wilh narrow-angle glaueoma, urinary retenl ion, or by patients reeei ving a monaamine oxidase (MAO ) inhibilor or within 14 days of stoppi ng use of an MAO inhibi tor.It also should not be used by patients with severe hypert ension or severeeoronary artery disease.
Pali ent s whoare or may beeome pregnant should betol d that Ihis produet should be used in pregnaney or during lactalian only il the potenti al benelit justifies the polential risk to the felus or nursing infant.
Pali ent s should beinstrueted not to break or chew thetabletand 10 take it with a full glass of water (see PRECAUTIONS : General , ADVERSE REACTIONS , OOSAGE ANO AOMINISTRATION). Drug Inleraelions: No speeifie interaetion sludies have been eondueled with CLARITlN-D 24 HOU R Extended Release Tablets. However, lorat adine (10 mg onee dai ly) has been safely eoadministered with therapeulie doses of erylhromyein, ei melidine, and ketoeonazole in eonl rolled elinieal pharmaeology studies. Although inereased pl asma eoneentratio ns (AUC0-24 hrs) of loratadine and/or desearboethoxyl oratadine were observed lollowing eoadministralion 01loratadine with eaeh of Ihese drugs in normal vol unteers (n = 24 in eaeh sludy) , there were no eli nieally relevantehanges in the safe ty profile of loratad ine, asassessed by eleetroeardiog raphie parameters, el inieal laboratorylests, vital signs, andadverse events. Therewereno signifieanl efleets on OT, intervals, and no reportsof sedationor syncape, No efleets on plasma eoneenlralions of eimetidine or ketoeonazole were observed . Plasma eoneentrations (AUC 0-24 hrs) of erythromyein deereased 15% with eoad mi nist ration of loratadine rela-tivetoIhat observe d with erythromyein alane. Theeli nieal relevanee of this diflerenee is unknown. These above findings are summarized in the followi ngtable:
Elleels onPlasma A CLUSTER OF ACOUSTIC NEUROMAS IN FISH HATCHERY W ORKERS ence of an exogenou s met aboli zing sys te m, but is not in several oth er stra ins." It is markedly cytotoxic , indu cing cell tran sformation and lip id peroxid ation in mammalian cells." Th e result s of carcin ogeni city assays ha ve been equi vocal, but the dye does appea r to act as a tumor promoter.' ? Mal achite green was nom inated as a priorit y chemi cal for ca rcinogenicity testin g by the Nati on al Toxicol ogy Program in 1993, based on the potential for significant work er and consumer ex pos ure, evidenc e of tumor promotion in rode nt livers, and a suspicion of ca rcinoge nicity based on its chemic al structure." Testin g dat a are not yet available.
Data gath ering, Th is investigation pro vides an example of ho w diffi cult it can be to identify occ upational neopla sm s. One probl em is the difficulty of identifying other cases, which is necessary to conduct epidemiologic studies. We considered obt ainin g informati on from health insur ance records, but the task was not practicable: FWS employees are scattered throu ghout the U.S., and their health eare is pro vided by approximately 350 different heal th plans. Furthermore , these plans are required to keep el aims data for only 3 yea rs, which is not a lon g enough peri od to identify a sufficient number of cases of a condition as rare as aco ustic neuroma. We also con sidered obta ining data from tumor reg istries, but not all states have them . Even among tho se that do , data coll ection is not uniform. For example, onl y 24 state reg istries collect information on beni gn tum ors. Of equ al concern is the lack of information about a patient ' s occupation and indu stry, despite the federal go vernment ' s efforts to eneourage the inelu sion of this info rmati on . The National Pro gram of Cancer Registries (NPCR), established in 1992 , call s for funded states to es tablish statewide , population-based registries and obtain uniform data elements in com plian ce with standar ds for completeness, timeliness, and quality. Although the NPCR requires the rep orting of each patient' s usual occupation and indu stry if this information is rec orded in the clinical record, this information is often missing.
Usual occupation and industry. Usual occupation and indu stry refers to any give n person ' s longest-h eld occup ation and the indu stry in whic h he or she work ed . Because the latency of neopl asms is so long, epidemiologists prefer to consider a per son ' s usual occ upation and industry rather than his or her current or latest occupation and indu str y. The coding of occup ation s and indu stries by healtheare profession als should be in accordance with the system used by the U.S. Census Bureau , which groups thou sand s of job title s int o approx imately 500 occ upation s and 200 industries ." It is impor tant that phy sicians document this inform ation in medical records, not only as part of the med ical history , but so that it is there for state registrie s to abstract. The NPCR does not require the reportin g of non invasive tum ors such as acoustic neuroma.
Th e Acou stic Neuroma Association (ANA), he adquar-Volume 79, Number 1 tered in Atl ant a, not only pro vide s support for patients, but act s as an information sourc e for healthe are pro fessionals, promotes research, and educa tes the publi c on sympto ms, thu s facilita ting early diagno sis.'?In 1989 , the ANA establ ished the Acou stic Neuroma Registry. Cases are repo rted voluntarily by surgeons (to obtain rep ort ing form s, contact the regist ry at P.O . Box 1240 2, Atlanta, GA 30355 ; phone: (404 ) 237-8023). Unfortun ately, no information regarding work history is collec ted either from ANA members or by the registry. Th e establishment of a comprehensive sys tem of coll ect ing information on occupation and indu stry in both the registry and membership would en able researchers to conduct epidemiolog ic studies to ev aluate possibl e associatio ns between workrelated ex pos ures and acou stic neurom a.
